Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07216066 | First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) | PHASE1 | RECRUITING | 46 | — | — | Dec 5, 2025 | Jun 7, 2029 | Apr 14, 2026 | 2 | Canada, Netherlands |
| Arm | Type | Description |
|---|---|---|
| ALN-SNCA Dose Escalation | EXPERIMENTAL | - |
| Matching Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-SNCA | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Diagnosis of Parkinson's disease according to the Movement Disorder Society (MDS) criteria, as assessed by the investigator, with bradykinesia plus at least one of the other cardinal signs of Parkinson's disease (resting tremor, rigidity), without any other known or suspe...